Metabolic syndrome and lung function in schizophrenia: A pilot study

Psychiatry Research

Volumn 220, Issue 1-2, 2014, Pages 58-62

  Vancampfort, Davy ^a,b   Probst, Michel ^a,b   Stubbs, Brendon ^c   Soundy, Andrew ^d   De Herdt, Amber ^b   De Hert, Marc ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b KU LEUVEN DEPARTMENT OF REHABILITATION SCIENCES   (Belgium)

^c UNIVERSITY OF GREENWICH   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Exercise; Metabolic syndrome; Physical activity; Physical fitness; Psychosis; Spirometry

Indexed keywords

CHLORPROMAZINE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; EXERCISE TEST; FEMALE; FITNESS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL ACTIVITY; PILOT STUDY; PREVALENCE; QUESTIONNAIRE; SCHIZOPHRENIA; SPIROMETRY; WAIST CIRCUMFERENCE; COMORBIDITY; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADULT; COMORBIDITY; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PILOT PROJECTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCHIZOPHRENIA;

EID: 84908258819     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.06.008     Document Type: Article

References (48)

1. Aaron S.D., Dales R., Cardinal P. How accurate is spirometry at predicting restrictive pulmonary impairment?. Chest 1999, 115:869-887.
2. Agarwal S.K. Abnormal lung function in schizophrenic patients. European Psychiatry 2012, 27(1):S1.
3. Ainsworth B.E., Haskell W.L., Whitt M.C., Irwin M.L., Swartz A.M., Strath S.J., O'Brien W.L., Bassett D.R., Schmitz K.H., Emplaincourt P.O., Jacobs D.R., Leon A.S. Compendium of physical activities: an update of activity codes and MET intensities. Medicine and Science in Sports and Exercise 2000, 32:498-504.
4. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabetes Medicine 2006, 23:469-480.
5. American Thoracic Society Standardization of spirometry, 1994 update. American Journal of Respiratory and Critical Care Medicine 1995, 152:1107-1136.
6. American Thoracic Society ATS statement: guidelines for the six-minute walk test. American Journal of Respiratory and Critical Care Medicine 2002, 166:111-117.
7. Chance W.W., Rhee C., Yilmaz C., Dane D.M., Pruneda M.L., Raskin P., Hsia C.C. Diminished alveolar microvascular reserves in type 2 diabetes reflect systemic microangiopathy. Diabetes Care 2008, 31(8):1596-1601.
8. Copeland L.A., Mortensen E.M., Zeber J.E., Pugh M.J., Restrepo M.I., Dalack G.W. Pulmonary disease among inpatient decedents: impact of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 31:720-726.
9. Craig C.L., Marshall A.L., Sjöström M., Bauman A.E., Booth M.L., Ainsworth B.E., Pratt M., Ekelund U., Yngve A., Sallis J.F., Oja P. International physical activity questionnaire: 12-country reliability and validity. Medicine and Science in Sports and Exercise 2003, 35:1381-1395.
10. De Hert M., Bussel J., Lindström E., Abrahams F., Fransen C., Peuskens J. PECC, Psychosis Evaluation tool for Common use by Caregivers 1998, EPO, Antwerpen.
11. De Hert M., Wampers M., Thys E., Wiselgen I., Lindström E., Peuskens J. Validation study of PECC (Psychosis Evaluation tool for Common use by Caregivers): interscale validity and inter-rater reliability. International Journal of Psychiatry in Clinical Practice 2002, 6:135-140.
12. De Hert M., Van Eyck D., Hanssens L., Peuskens H., Thys E., Wampers M., Scheen A., Peuskens J. Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics?. European Psychiatry 2006, 21:224-226.
13. De Hert M., Correll C., Bobes J., Cetkovich-Bakmas M., Cohen D., Asai I., Detraux J., Gautam S., Moller H., Ndetei D., Newcomer J., Uwakwe R., Leucht S. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011, 10(1):52-77.
14. Faulkner G., Cohn T., Remington G. Validation of a physical activity assessment tool for individuals with schizophrenia. Schizophrenia Research 2006, 82:225-231.
15. Fimognari F.L., Pasqualetti P., Moro L., Franco A., Piccirillo G., Pastorelli R., Rossini P.M., Incalzi R.A. The association between metabolic syndrome and restrictive ventilator dysfunction in older persons. Journal of Gerontology Series A, Biological Sciences and Medical Sciences 2007, 62(7):760-765.
16. Ford E.S., Mannino D.M. Prospective association between lung function and the incidence of diabetes: findings from the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Diabetes Care 2004, 27(12):2966-2970.
17. Gale E. Should we dump the metabolic syndrome?. British Medical Journal 2008, 336:641.
18. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. American Journal of Psychiatry 2010, 167:686-693.
19. Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2013. From the Global Strategy for the Diagnosis, Management and Prevention of COPD. Available from: http://www.goldcopd.org/.
20. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. population. American Journal of Respiratory Critical Care Medicine 1999, 159:179-187.
21. Himelhoch S., Lehman A., Kreyenbuhl J., Daumit G., Brown C., Dixon L. Prevalence of chronic obstructive pulmonary disease among those with serious mental illness. American Journal of Psychiatry 2004, 161(12):2317-2319.
22. Hoang U., Stewart R., Goldacre M.J. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. British Medical Journal 2011, 343:d5422.
23. Hole D.J., Watt G.C., Davey-Smith G., Hart C.L., Gillis C.R., Hawthorne V.M. Impaired lung function and mortality risk inmen and women: findings from the Renfrew and Paisley prospective population study. British Medical Journal 1996, 31(3):711-715.
24. Lam K.B., Jordan R.E., Jiang C.Q., Thomas G.N., Miller M.R., Zhang W.S., Lam T.H., Cheng K.K., Adab P. Airflow obstruction and metabolic syndrome: the Guangzhou Biobank Cohort Study. European Respiratory Journal 2010, 35(2):317-323.
25. Lessard A., Alméras N., Turcotte H., Tremblay A., Després J.P., Boulet L.P. Adiposity and pulmonary function: relationship with body fat distribution and systemic inflammation. Clinical & Investigative Medicine 2011, 34(2):64-70.
26. Leone N., Courbon D., Thomas F., Bean K., Jego B., Leynaert B., Guize L., Zureik M. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. American Journal of Respiratory and Critical Care Medicine 2009, 179:509-516.
27. Lin W.Y., Yao C.A., Wang H.C., Huang K.C. Impaired lung function is associated with obesity and metabolic syndrome in adults. Obesity 2006, 14:1654-1661.
28. Mannino D.M., Buist A.S., Petty T.L., Enright P.L., Redd S.C. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003, 58:388-393.
29. Mannino D.M, Ford E.S., Redd S.C. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. American Journal of Medicine 2003, 114(9):758-762.
30. Mannino D.M., Holguin F., Pavlin B.I., Ferdinands J.M. Riskfactor for prevalence of and mortality related to restriction on spirometry: findings from the First National Health and Nutrition Examination Survey and follow-up. International Journal of Tuberculosis and Lung Disease 2005, 9:613-621.
31. Manu P., Correll C.U., Wampers M., Mitchell A.J., Probst M., Vancampfort D., De Hert M. Markers of inflammation in schizophrenia: association vs. causation. World Psychiatry 2014, 13(2):189-192.
32. Martens P.J., Chochinov H.M., Prior H.J. Where and how people with schizophrenia die: a population-based, matched cohort study in Manitoba, Canada. Journal of Clinical Psychiatry 2013, 74(6):e551-e557.
33. Mitchell A., Vancampfort D., De Herdt A., Yu W., De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophrenia Bulletin 2013, 39(2):295-305.
34. Mitchell A., Vancampfort D., Sweers K., van Winkel R., Yu W., De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders. A systematic review and meta-analysis. Schizophrenia Bulletin 2013, 39(2):306-318.
35. Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nature Reviews Immunology 2011, 11(2):85-97.
36. Ozbulut O., Genc A., Bagcioglu E., Coskun K.S., Acar T., Alkoc O.A., Karabacak H., Sener U., Ucok K. Evaluation of physical fitness parameters in patients with schizophrenia. Psychiatry Research 2013, 210(3):806-811.
37. Scarlata S., Fimognari F.L., Moro L., Pastorelli R., Antonelli-Incalzi R. Metabolic syndrome and impaired lung function. Chest 2010, 137(2):494.
38. Scarlata S., Fimognari F.L., Cesari M., Giua R., Franco A., Pasqualetti P., Pastorelli R., Antonelli-Incalzi R. Lung function changes in older people withmetabolic syndrome and diabetes. Geriatrics & Gerontology International 2013, 13(4):894-900.
39. Sin D.D., Wu L., Man S.F. The relationship between reduced lungfunction and cardiovascular mortality: a population-basedstudy and a systematic review of the literature. Chest 2005, 127:1952-1959.
40. Soundy A., Taylor A., Faulkner G., Rowlands A. Psychometric properties of the 7-day physical activity recall questionnaire in individuals with severe mental illness. Archives of Psychiatric Nursing 2007, 21(6):309-316.
41. Soundy A., Roskell C., Stubbs B., Vancampfort D. Selection, use and psychometric properties of physical activity measures to assess individuals with severe mental illness; a narrative synthesis. Achives of Psychiatric Nursing 2014, 28(2):135-151.
42. Vancampfort D., Probst M., Sweers K., Maurissen K., Knapen J., De Hert M. Reliability minimal detectable changes, practice effects and correlates of the 6-min walk test inpatients with schizophrenia. Psychiatry Research 2011, 187:62-67.
43. Vancampfort D., Probst M., Knapen J., Carraro A., De Hert M. Associations between sedentary behaviour and metabolic parameters in patients with schizophrenia. Psychiatry Research 2012, 126(1):12-20.
44. Vancampfort D., Wampers M., Mitchell A.J., Correll C.U., De Herdt A., Probst M., De Hert M. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013, 12(3):240-250.
45. Vancampfort D., Probst M., Scheewe T., De Herdt A., Sweers K., Knapen J., van Winkel R., De Hert M. Relationships between physical fitness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia. Psychiatry Research 2013, 207:25-32.
46. Vancampfort D., Probst M., De Herdt A., Corredeira R.M., Carraro A., De Wachter D., De Hert M. An impaired health related muscular fitness contributes to a reduced walking capacity in patients with schizophrenia: a cross-sectional study. BMC Psychiatry 2013, 13:5.
47. van Winkel R., De Hert M., Van Eyck D., Hanssens L., Wampers M., Scheen A., Peuskens J. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. Journal of Clinical Psychiatry 2006, 67:1493-1500.
48. Wannamethee S.G., Shaper A.G., Rumley A., Sattar N., Whincup P.H., Thomas M.C., Lowe G.D. Lung function and risk of type 2 diabetes and fatal and nonfatal major coronary heart disease events: possible associations with inflammation. Diabetes Care 2010, 33(9):1990-1996.